Bruker (NASDAQ:BRKR) Earns Neutral Rating from Analysts at UBS Group

UBS Group assumed coverage on shares of Bruker (NASDAQ:BRKR) in a report issued on Wednesday morning, Marketbeat reports. The firm issued a neutral rating and a $65.00 target price on the medical research company’s stock.

BRKR has been the topic of a number of other research reports. Barclays raised their price objective on shares of Bruker from $53.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, June 24th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Wolfe Research started coverage on shares of Bruker in a research report on Monday, June 1st. They issued a “peer perform” rating on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, August 31st. Finally, Citigroup cut their price objective on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Bruker presently has a consensus rating of “Hold” and a consensus target price of $57.00.

Bruker Stock Performance

Shares of BRKR opened at $53.43 on Wednesday. The firm has a market capitalization of $8.14 billion, a P/E ratio of -76.33, a PEG ratio of 1.64 and a beta of 1.26. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. Bruker has a one year low of $30.09 and a one year high of $65.30. The business has a fifty day moving average of $58.25 and a 200 day moving average of $49.25.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts anticipate that Bruker will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -28.57%.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently made changes to their positions in the business. Arizona State Retirement System raised its stake in Bruker by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 29,402 shares of the medical research company’s stock valued at $1,769,000 after purchasing an additional 188 shares during the period. Allworth Financial LP grew its holdings in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Federated Hermes Inc. raised its position in shares of Bruker by 6.7% during the fourth quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after buying an additional 380 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Bruker by 121.0% during the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares during the last quarter. Finally, IFP Advisors Inc lifted its holdings in shares of Bruker by 88.6% in the second quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company’s stock worth $64,000 after buying an additional 498 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.